Business Context and Reporting Period
Company: Lyell Immunopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 26, 2024
Subject: Disclosure of initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product candidate enhanced with proprietary anti-exhaustion technology for advanced solid tumors.
Key Financial Metrics
This filing is a non-financial event report (Regulation FD Disclosure and Other Events). It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Data
The report details initial data from 20 treated patients (16 with triple-negative breast cancer [TNBC], 4 with non-small cell lung cancer) who had relapsed/refractory metastatic disease with a mean of six prior lines of therapy.
- Efficacy (TNBC at 150 x 10^6 cells dose): Objective Response Rate (ORR) of 40%; Clinical Benefit Rate (CBR) of 60%.
- Efficacy (All Dose Levels): CBR of 38% across all evaluable dose levels.
- Safety Profile:
- Most frequent related adverse events (any grade): Cytokine release syndrome (61%, Grade 1-2), pneumonitis (22%), headache (17%), and cytopenia.
- Most frequent Grade ≥ 3 related adverse events: Pneumonitis (17%), hypoxia (11%), and cytopenia (78%).
- One patient experienced Grade 5 respiratory failure on Day 41.
- No reports of immune effector cell-associated neurotoxicity syndrome (ICANS) attributed to LYL797.
- Translational Findings: CAR T cells demonstrated expansion, infiltration, and persistence in solid tumors. Median peak expansion was approximately three-fold higher at the 150 x 10^6 dose compared to the 50 x 10^6 dose. Low levels of the exhaustion marker TIGIT were observed, supporting the anti-exhaustion technology.
Outlook, Risks, and Management Commentary
Management Commentary: The data supports the ability of LYL797 to infiltrate and persist in the solid tumor microenvironment. The company is continuing dose escalation separately and more gradually in patients with lung metastases due to pneumonitis instances. All patients are now receiving prophylactic steroids prior to treatment.
Risks and Contingencies:
- Pneumonitis: Observed in patients with lung metastases; requires careful dose escalation management.
- Severe Adverse Events: One Grade 5 respiratory failure event occurred.
- Development Stage: Data is from a Phase 1 trial with a limited patient cohort (20 treated).
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and the clinical presentation (Exhibit 99.2) for detailed statistical tables and patient demographics.
- Confirm the specific protocol for dose escalation in patients with lung metastases following the pneumonitis observations.
- Monitor future filings for updates on the Grade 5 respiratory failure event and its resolution.
- Review the company's cash runway in subsequent 10-Q or 10-K filings, as this 8-K does not address liquidity.